Genentech

VABYSMO

Manufacturer:

Genentech

Vabysmo HCPCS:

J2777

HCPCS Code Descriptor:

Injection, faricimab-svoa, 0.1 mg

Category:

J Code

Vabysmo NDCs:

50242-0096-01

Primary Type:

Opthalmic

Generic/Specialty Status:

Single-Source

Route of Administration:

Intraocular

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Vabysmo:

VABYSMO is an Opthalmic drug manufactured by Genentech and administered via the Intraocular route of administration. The J Code: J2777 is aligned to the drug VABYSMO.

VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (ANG-2) inhibitor recommended for treatment of Neovascular (Wet) Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME). VABYSMO (J2777) is a bispecific antibody that binds both VEGF-A and Ang-2 with the goal of inhibiting new vascular growth and permeability while supporting vascular stability and making blood vessels less senstitive to VEGF-A. VABYSMO may be prescribed to individuals over the age of 65 more often. Patient assistance for this medication can be found through Genentech.

ACCESS PRICING AND MORE BY REGISTERING

J2777 Added Date:

October 1, 2022

J2777 Effective Date:

October 1, 2022

J2777 Termination Date:

HCPCS Active

Vabysmo billing and coding information can be found through Genentech at the link below:
Vabysmo patient assistance information can be found through Genentech at the URL: https://www.gene.com/patients/patient-foundation/apply-for-help#patients
VABYSMO prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for VABYSMO. Please check back in a few weeks.